GALT
Companies
NASDAQ
Galectin Therapeutics Inc.
Health Care
$3.29
+$1.12 (+86.82%)
Price Chart
Overview
About GALT
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Market Cap
$161.6M
Volume
841.9K
Avg. Volume
848.9K
P/E Ratio
-0.8630953
Dividend Yield
0.00%
Employees
33.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.14
Moderate Correlation
Volatility
High (0.95)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, GALT shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025